Table 1.
Distribution of worst histologic diagnosis in 331,818 women over 2003-2009 by enrollment HPV test and Pap smear.
| Histology diagnosis | no biopsy or <CIN2 | CIN2 | CIN3/AIS | AIS | Squamous Carcinoma |
Adeno- Carcinoma |
Total Cancers |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # | % | # | % | # | % | # | % | # | % | # | % | # | % | # | % | |
| Total | 331818 | 100.00% | 329508 | 100.00% | 1476 | 100% | 747 | 100% | 70 | 100% | 49 | 100% | 27 | 100% | 87 | 100% |
| Baseline HPV | ||||||||||||||||
| Negative | 315061 | 94.95% | 314589 | 95.47% | 322 | 22% | 123 | 16% | 14 | 20% | 18 | 37% | 6 | 22% | 27 | 31% |
| Positive | 16757 | 5.05% | 14919 | 4.53% | 1154 | 78% | 624 | 84% | 56 | 80% | 31 | 63% | 21 | 78% | 60 | 69% |
| Baseline Pap | ||||||||||||||||
| Pap− | 319177 | 96.19% | 318093 | 96.54% | 687 | 47% | 354 | 47% | 42 | 60% | 15 | 31% | 23 | 85% | 43 | 49% |
| Total Pap+ | 12641 | 3.81% | 11415 | 3.46% | 789 | 53% | 393 | 53% | 28 | 40% | 34 | 69% | 4 | 15% | 44 | 51% |
| ASCUS | 8517 | 2.57% | 8106 | 2.46% | 283 | 19% | 123 | 16% | 12 | 17% | 4 | 8% | 1 | 4% | 5 | 6% |
| LSIL | 2527 | 0.76% | 2208 | 0.67% | 253 | 17% | 61 | 8% | 1 | 1% | 4 | 8% | 0 | 0% | 5 | 6% |
| AGUS, NOS | 764 | 0.23% | 705 | 0.21% | 26 | 2% | 27 | 4% | 7 | 10% | 1 | 2% | 2 | 7% | 6 | 7% |
| ASC-H, HSIL+ | 833 | 0.25% | 396 | 0.12% | 227 | 15% | 182 | 24% | 8 | 11% | 25 | 51% | 1 | 4% | 28 | 32% |
| Baseline HPV/Pap | ||||||||||||||||
| HPV−/Pap− | 306969 | 92.51% | 306597 | 93.05% | 258 | 17% | 96 | 13% | 11 | 16% | 10 | 20% | 6 | 22% | 18 | 21% |
| HPV−/Pap+ | 8092 | 2.44% | 7992 | 2.43% | 64 | 4% | 27 | 4% | 3 | 4% | 8 | 16% | 0 | 0% | 9 | 10% |
| HPV+/Pap− | 12208 | 3.68% | 11496 | 3.49% | 429 | 29% | 258 | 35% | 31 | 44% | 5 | 10% | 17 | 63% | 25 | 29% |
| HPV+/Pap+ | 4549 | 1.37% | 3423 | 1.04% | 725 | 49% | 366 | 49% | 25 | 36% | 26 | 53% | 4 | 15% | 35 | 40% |
| Baseline HPV/ASC-US | ||||||||||||||||
| HPV-/ASC-US | 6496 | 1.96% | 6455 | 1.96% | 25 | 2% | 14 | 2% | 1 | 1% | 2 | 4% | 0 | 0% | 2 | 2% |
| HPV+/ASC-US | 2021 | 0.61% | 1651 | 0.50% | 258 | 17% | 109 | 15% | 11 | 16% | 2 | 4% | 1 | 4% | 3 | 3% |
Abbreviations: Cervical Intraepthelial Neoplasia Grade 2 (CIN2), Cervical Intraepthelial Neoplasia Grade 3 or adenocarcinoma in situ (CIN3/AIS). Total Cancers includes squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma, and cervical cancer of unknown histology. CIN3/AIS includes 13 histologies that were either CIN3 or AIS, but precisely which is unknown. Conventional Pap tests were reported according to the 2001 Bethesda System17 (in order of increasing severity): no intraepithelial lesion or malignancy (NILM or Pap-negative or normal Pap test); atypical squamous-cells of undetermined significance (ASC-US); low-grade squamous intraepithelial lesion (LSIL); atypical glandular cells of undetermined significance or not otherwise specified (AGUS/NOS); atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesion (ASC-H); high-grade squamous intraepithelial lesion (HSIL); or squamous-cell carcinoma (SCC). “Pap-positive” means ASC-US or more severe cytology. We grouped ASC-H, HSIL, and SCC into a single high-risk Pap category because each is individually uncommon and their CIN3+ risks were similarly increasedb.